



1 PW

I hereby Certify that this Correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 4, 2004

Susan L. Eick

Name

Susan L. Eick

Signature

November 4, 2004

Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Wang et al.

Filed: December 5, 2003

Serial No. 10/728,491

For: High Efficacy Antisense RI_α PKA Poly-DNP Oligoribonucleotides

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant wishes to make of record the references listed in the attached Form 1449. Legible copies of the references listed are enclosed.


It is believed that no fee is due. However, if that is incorrect, the Examiner is authorized to charge any fee due to Deposit Account No. 08-2442.

Respectfully submitted,

By: 

Ranjana Kadfe, Reg. No. 40,041

HODGSON RUSS LLP
One M & T Plaza, Suite 2000
Buffalo, New York 14203-2391
Tel: (716) 848-1628
Dated: November 4, 2004



Please type a plus sign inside the box +

PTO/SB/08A(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/728,491
Filing Date	December 5, 2003
First Named Inventor	Wang et al.
Art Unit	
Examiner Name	
Attorney Docket Number	11520.0338

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-5,496,546	03-05-1996	Wang et al.	
	2	US-6,291,438 B1	09-18-2001	Wang	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/728,491			
	Filing Date	December 5, 2003			
	First Named Inventor	Wang et al.			
	Group Art Unit				
	Examiner Name				
Sheet	2	of	3	Attorney Docket Number	11520.0338

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	ASHUN et al., <i>Inhibition of Murine Leukemia virus with Poly2'-O-(2, 4-Dinitrophenyl) Poly [A]</i> , Antimicrobial Agents and Chemotherapy (Oct. 1996) Vol. 40, No. 10, pp. 2311-2317	
	2	BRADBURY et al., <i>Protein Kinase A (PK-A) Regulatory Subunit Expression in Colorectal Cancer and Related Mucosa</i> , Brit. J. Cancer (1994) Vol. 69, pp. 738-742	
	3	CHEN et al., <i>Poly-2'-DNP-RNAs with Enhanced Efficacy for Inhibiting Cancer Cell Growth</i> , Oligonucleotides (2004) Vol. 14, pp. 90-99	
	4	CHO-CHUNG, <i>Antisense DNA Toward Type I Protein Kinase A Produces Sustained Inhibition of Tumor Growth</i> , Proceedings of the Assoc. of American Physicians (1997) Vol. 109, No. 1, pp. 23-32	
	5	KANG et al., <i>Design of Structure-Based Reverse Transcriptase Inhibitors</i> , The Journal of Biological Chemistry (April 2, 1994) Vol. 269, No. 16, pp. 12024-12031	
	6	MILLER et al., <i>Types of Cyclic AMP Binding Proteins in Human Breast Cancers</i> , Eur. J. Cancer (1993) Vol. 29A, No. 7, pp. 989-991	
	7	NESTEROVA et al., <i>A Single-Injection Protein Kinase A-Directed Antisense Treatment to Inhibit Tumour Growth</i> , Nature Medicine (June 1995) Vol. 1, No. 6, pp. 528-533	
	8	NESTEROVA et al., <i>Oligonucleotide Sequence-Specific Inhibition of Gene Expression, Tumor Growth Inhibition, and Modulation of cAMP Signaling by an RNA-DNA Hybrid Antisense Targeted to Protein Kinase A RIα Subunit</i> , Antisense & Nucleic Acid Drug Development (2000) Vol. 10, pp. 423-433	
	9	RAHMAN et al., <i>Selective Removal of Ribonucleases from Solution with Covalently Anchored Macromolecular Inhibitor</i> , Analytical chemistry (January 1, 1996) Vol. 68, No. 1, pp. 136-138	
	10	RU et al., <i>Specific Inhibition of Breast Cancer Cells by Antisense Poly-DNP-Oligoribonucleotides and Targeted Apoptosis</i> , Oncology Research (1998) Vol. 10, pp. 389-397	
	11	RU et al., <i>Growth Inhibition and Antimetastatic Effect of Antisense Poly-DNP-RNA on Human Breast Cancer Cells</i> , Oncology Research (1999) Vol. 11, pp. 505-512	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/728,491		
		Filing Date	December 5, 2003		
		First Named Inventor	Wang et al.		
		Group Art Unit			
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	11520.0338

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	SHEN et al., <i>A High-Efficacy Antisense RIα Poly-DNP 21-nt RNA</i> , Antisense and Nucleic Acid Drug Development (2003) Vol. 13, pp. 67-74	
	13	SUMMERTON, <i>Intracellular Inactivation of Specific Nucleotide Sequences: A General Approach to the Treatment of Viral Diseases and Virally-Mediated Cancers</i> , J. Theor. Biol. (1979) Vol. 78, pp. 77-99	
	14	SUMMERTON et al., <i>Morpholino Antisense Oligomers: Design, Preparation, and Properties</i> , Antisense & Nucleic Acid Drug Development (1997) Vol. 7, pp. 187-195	
	15	TORTORA et al., <i>The RIα Subunit of Protein Kinase A Controls Serum Dependency and Entry into Cell Cycle of Human Mammary Epithelial Cells</i> , Oncogene (1994) Vol. 9, pp. 3233-3240	
	16	WANG, Aihong et al., <i>Effective Treatment of Murine Leukemia with Antisense Poly-2'-O-(2,4-Dinitrophenyl)-Oligoribonucleotides</i> , Antisense & Nucleic Acid Drug Development (1999) Vol. 9, pp. 43-51	
	17	WANG, Hui et al., <i>Antitumor Activity and Pharmacokinetics of a Mixed-Backbone Antisense Oligonucleotide Targeted to the RIα Subunit of Protein Kinase A After Oral Administration</i> , Proc. Natl. Acad. Sci. (November 23, 1999) Vol. 96, No. 24, pp. 13989-13994	
	18	XIN et al., <i>Treatment of Duck Hepatitis B. Virus by Antisense Poly-2'-O-(2,4-Dinitrophenyl)-Oligoribonucleotides</i> , Antisense & Nucleic Acid Drug Development (1998) Vol. 8, pp. 459-468	
	19	ZAMECNIK et al., <i>Inhibition of Rous Sarcoma Virus Replication and Cell Transformation by a Specific Oligodeoxynucleotide</i> , Proc. Natl. Acad. Sci. (January 1978) Vol. 75, No. 1, pp. 280-284	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number. ² Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.